-
Taxonomy & unit
-
us-gaap: USD
-
Description
-
The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business).
-
Summary
-
Allogene Therapeutics, Inc. quarterly/annual Nonoperating Income (Expense) history and growth rate from Q3 2018 to Q2 2024.
- Allogene Therapeutics, Inc. Nonoperating Income (Expense) for the quarter ending June 30, 2024 was $5.07M, a 288% increase year-over-year.
- Allogene Therapeutics, Inc. Nonoperating Income (Expense) for the twelve months ending June 30, 2024 was $9.62M.
- Allogene Therapeutics, Inc. annual Nonoperating Income (Expense) for 2023 was $472K.
- Allogene Therapeutics, Inc. annual Nonoperating Income (Expense) for 2022 was -$4.88M, a 162% decline from 2021.
- Allogene Therapeutics, Inc. annual Nonoperating Income (Expense) for 2021 was -$1.86M, a 96.8% increase from 2020.
Nonoperating Income (Expense), Trailing 12 Months (USD)
Nonoperating Income (Expense), Quarterly (USD)
Nonoperating Income (Expense), YoY Quarterly Growth (%)